Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CRBU NASDAQ:GYRE NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.34+0.9%$4.59$1.39▼$5.69$738.82M0.761.89 million shs2.40 million shsCRBUCaribou Biosciences$1.76$1.96$1.24▼$3.54$174.56M2.372.42 million shs1.69 million shsGYREGyre Therapeutics$6.52-1.1%$6.55$5.44▼$9.42$734.71M1.89117,918 shs82,563 shsRLMDRelmada Therapeutics$6.39-7.7%$6.90$0.55▼$8.00$725.84M0.412.39 million shs2.14 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+5.38%+7.52%+16.26%+27.78%+272.54%CRBUCaribou Biosciences-0.56%+6.02%-25.42%-11.56%+39.68%GYREGyre Therapeutics+2.17%+7.50%+11.51%-8.85%-10.34%RLMDRelmada Therapeutics-0.86%+2.22%-4.02%-2.54%+1,052.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.34+0.9%$4.59$1.39▼$5.69$738.82M0.761.89 million shs2.40 million shsCRBUCaribou Biosciences$1.76$1.96$1.24▼$3.54$174.56M2.372.42 million shs1.69 million shsGYREGyre Therapeutics$6.52-1.1%$6.55$5.44▼$9.42$734.71M1.89117,918 shs82,563 shsRLMDRelmada Therapeutics$6.39-7.7%$6.90$0.55▼$8.00$725.84M0.412.39 million shs2.14 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+5.38%+7.52%+16.26%+27.78%+272.54%CRBUCaribou Biosciences-0.56%+6.02%-25.42%-11.56%+39.68%GYREGyre Therapeutics+2.17%+7.50%+11.51%-8.85%-10.34%RLMDRelmada Therapeutics-0.86%+2.22%-4.02%-2.54%+1,052.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50115.36% UpsideCRBUCaribou Biosciences 2.75Moderate Buy$8.67392.42% UpsideGYREGyre Therapeutics 2.00Hold$17.00160.74% UpsideRLMDRelmada Therapeutics 2.75Moderate Buy$12.0087.79% UpsideCurrent Analyst Ratings BreakdownLatest CRBU, RLMD, GYRE, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M95.25N/AN/A$0.85 per share6.28CRBUCaribou Biosciences$11.16M15.64N/AN/A$1.31 per share1.34GYREGyre Therapeutics$116.59M6.23$0.22 per share29.66$1.48 per share4.41RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/11/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)Latest CRBU, RLMD, GYRE, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CRBUCaribou BiosciencesN/A6.226.22GYREGyre TherapeuticsN/A4.644.06RLMDRelmada TherapeuticsN/A18.2518.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CRBUCaribou Biosciences77.51%GYREGyre Therapeutics23.99%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CRBUCaribou Biosciences8.54%GYREGyre Therapeutics9.50%RLMDRelmada Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableGYREGyre Therapeutics40111.49 million100.90 millionNo DataRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableCRBU, RLMD, GYRE, and ACRS HeadlinesRecent News About These CompaniesRelmada Therapeutics Joins Russell 2000 Index And Russell 3000 IndexJune 29 at 7:30 AM | benzinga.comRelmada Therapeutics Joins Russell 2000® and Russell 3000® IndexesJune 29 at 7:00 AM | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 28 at 4:11 AM | americanbankingnews.comQ2 Earnings Estimate for RLMD Issued By HC WainwrightJune 22, 2026 | americanbankingnews.comRelmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock TodayJune 19, 2026 | seekingalpha.comRelmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy NowJune 19, 2026 | finance.yahoo.comRelmada's cancer drug candidate sparks fresh bullish callJune 18, 2026 | msn.comRelmada Therapeutics IncJune 12, 2026 | edition.cnn.comRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone ProgramJune 11, 2026 | globenewswire.comRelmada Therapeutics Increases Authorized Shares After Shareholder VoteMay 28, 2026 | tipranks.comRelmada Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comRelmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...May 13, 2026 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comRelmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6, 2026 | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5, 2026 | globenewswire.comMizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comDoes Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?April 13, 2026 | zacks.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBU, RLMD, GYRE, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.34 +0.05 (+0.95%) Closing price 04:00 PM EasternExtended Trading$5.37 +0.03 (+0.56%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Caribou Biosciences NASDAQ:CRBU$1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.85%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Gyre Therapeutics NASDAQ:GYRE$6.52 -0.07 (-1.06%) Closing price 04:00 PM EasternExtended Trading$6.53 +0.01 (+0.15%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Relmada Therapeutics NASDAQ:RLMD$6.39 -0.53 (-7.66%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.03 (+0.45%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
